Additionally, Willis et al., in a study of 21 patients with SLE—64% positive for aCL IgG, 13% for aCL IgM, 65% for β2GP1 IgG, and 45% for β2GP1 IgM—found no significant differences in IL-6, IL-8, VEGF, sCD40L, IL-1β, TNF-α, CRP, ICAM-1, VCAM-1, aCL IgG, or aCL IgM levels, nor in disease activity as measured by the SLAM-R score, following statin treatment [132]. This evidence concerns the gene CD40LG and systemic lupus erythematosus.